China's medical products administrator granted Hutchmed (HKG:0013) breakthrough therapy designation for its combination of savolitinib and osimertinib for a mutation of non-small cell lung cancer, according to a Thursday filing with the Hong Kong Exchange.
The drug combination is undergoing phase 3 trials in China, the filing said.
The breakthrough designation is given to drugs that treat life-threatening illnesses with no known treatment options and with clinical evidence showing advantages over other existing therapies, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。